FindTrial
Sign In

Study to know the effects of using a chemotherapy drug named pazopanib in advanced soft tissue cancer at a cancer center

Pazopanib in metastatic soft tissue sarcoma experience from a tertiary cancer centre in India

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/01/011112
Enrollment
21
Registered
2018-01-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C499- Malignant neoplasm of connective and soft tissue, unspecified Health Condition 2: null- Pathologically confirmed soft tissue sarcoma patient who were treated with pazopanib based therapy during the study period

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Pathologically confirmed STS patient who were treated with pazopanib based therapy during the study period. 2.Availability of adequate clinico-pathological, treatment related details and follow-up records in EMR or case records of the patients.

Exclusion criteria

Exclusion criteria: 1.Patients who do not meet the above criteria. 2.Patients who has taken treatment for less than 3 months.

Design outcomes

Primary

MeasureTime frame
To assess 1.Response rates 2.Progression free survival 3.Grade III/IV toxicity (hematological and non-hematological) Timepoint: 2 and 5 years—

Secondary

MeasureTime frame
Overall survivalTimepoint: 2 and 5 years—

Countries

India

Contacts

Public ContactJyoti Bajpai

Tata Memorial Hospital

dr_jyotibajpai@yahoo.co.in02224177287

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026